Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05168306 · ClinicalTrials.gov registry record
T2 FSL2 Weight Loss
A clinical trial, sponsored by Abbott Diabetes Care.
- Terminated
- Registry status
- 43
- Enrollment target
NCT05168306: Clinical Trial study, sponsored by Abbott Diabetes Care.
NCT05168306 is a clinical trial that was terminated before completion, run by Abbott Diabetes Care. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05168306 was terminated before completion, sponsored by Abbott Diabetes Care.
- TERMINATED
- Registry status
- 43 participants
- Enrollment target
Study Summary
To compare the impact of the FreeStyle Libre (FSL) 2 Flash Glucose Monitoring System to the current Diabetes Monitoring standard of care (SOC) on weight reduction in subjects with type 2 diabetes.
Primary Outcome
Subjects' bodyweight will be measured during Visits 1, 3, 5 and 7. At the end of the 6 months period the bodyweight change, if any, will be assessed between the two Arms of the study.
Interventions
- DEVICE FreeStyle Libre 2 Flash Glucose Monitoring System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2021-12-05 |
| Est. Completion | 2023-07-19 |
Why NCT05168306 stopped before completion
NCT05168306 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which FreeStyle Libre 2 Flash Glucose Monitoring System is the first listed.
NCT05168306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05168306 about?
NCT05168306 is a clinical study titled "T2 FSL2 Weight Loss". To compare the impact of the FreeStyle Libre (FSL) 2 Flash Glucose Monitoring System to the current Diabetes Monitoring standard of care (SOC) on weight reduction in subjects with type 2 diabetes.
What is the current status of trial NCT05168306?
This trial is currently terminated. The enrollment target is 43 participants. The study started on 2021-12-05. Estimated completion is 2023-07-19.
What interventions are being tested in trial NCT05168306?
The interventions under investigation include: FreeStyle Libre 2 Flash Glucose Monitoring System (DEVICE).
Who is sponsoring clinical trial NCT05168306?
This trial is sponsored by Abbott Diabetes Care, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI